call with stephen, page-5

This Company doesn't seem to know when it's on a good thing with ArTiMist being recognised as one of the 5 most promising drugs in Phase 111 trials. But to me the management seems incapable of managing this project and I fear the trials will fail.
We read back in July that EMS were frustrated at delays in receiving updated trial information, and that they had not been informed by ProtoPharma of any deviation from expected completion date of end Q311. In other words they had no idea whether the trials were on track and didn't seem to be concerned enough to ask for clarification.
At that stage we had the following "progress"
50 patients treated at Rawanda
recruitment commenced Burkina Faso
approval received from Ghana
approval pending Tanzania & Uganda.
So here we are almost at the end of Q311 and we read that Ghana and Tanzania studies would not be initiated due to cash flow issues.
Yet Carter is claiming that funds have never been requested for Tanzania and Ghana - so why didn't that ring alarm bells when the project was meant to have been completed by now. How did they expect the trails to be completed without funding??
To think that it is nearly a week now and there has been no official clarification of this market sensitive release. Surely the ASX needs to step in and pull EMS into line. Why are shareholders sitting on their hands, apparently accepting the confusing and conflicting statements flying about? Am I the only one disgusted by these non-events?